Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)
Protalix BioTherapeutics (PLX) posted Notes Payables of $4.1 million for Q4 2020, down 5.0% on a QoQ basis from $4.3 million in Q3 2020, and down 5.0% year-over-year from $4.3 million in Q1 2020.
Powered by 
Analysis
Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020) Analysis & Trends
Protalix BioTherapeutics has reported Notes Payables for 2 years, with the latest figure at $4.1 million in Q4 2020.
- On a quarterly basis, Notes Payables fell 5.0% year-over-year to $4.1 million in Q4 2020; TTM through Dec 2020 was $4.1 million, a 5.0% decrease from a year earlier, with the FY2020 full-year figure at $4.1 million, down 5.0% from the prior year.
- Notes Payables was $4.1 million for Q4 2020 at Protalix BioTherapeutics, down from $4.3 million in the prior quarter.
- The five-year high for Notes Payables was $4.3 million in Q4 2019, with the low at $4.1 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 4.09 Mn |
| Sep 30, 2020 | 4.30 Mn |
| Jun 30, 2020 | 4.30 Mn |
| Mar 31, 2020 | 4.30 Mn |
| Dec 31, 2019 | 4.30 Mn |